Skip to content

Our Mission

Our Vision

The Leading Partner for Transplant Patients and The Transplant Ecosystem

Our Mission

We are committed to improving transplant patient outcomes through innovative, noninvasive testing solutions throughout the entire patient journey.

CareDx Highlights

LEADER IN TRANSPLANT MOLECULAR DIAGNOSTICS
  • Products across continuum of transplant diagnostics
  • AlloMap® used in 90% of heart transplant centers
  • Leadership position in cell free DNA (“Liquid Bx”)
  • AlloSure® used in +130 centers and on >5% of U.S. kidney transplant patients since launch
Genomic Information and Artificial Intelligence Drives Future Opportunity
  • Building platform for Artificial Intelligence in Transplant Care (AiTraC)
  • Outcome orientation along the transplant patient journey
  • 76% revenue growth in Q2 2019, FY revenue guidance raised to $123m to $125m
  • Achieved fourth consecutive quarter of adjusted EBITDA profitability
  • Strong, debt free balance sheet